The exclusive worldwide license agreement allows BiondVax to develop and commercialize a novel anti-IL-17 antibody for the treatment of autoimmune and inflammatory diseases, including psoriasis. This could potentially expand the company's product portfolio and address a significant market, positively impacting its stock price in the short term.